# Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT00517790** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 140 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** ABT-869 .25 mg/kg
- **DRUG:** ABT-869 0.10 mg/kg

## Key facts

- **NCT ID:** NCT00517790
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2011-06
- **Final completion:** 2012-06
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2013-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517790, "Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00517790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*